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Hepcidin inchronic liverdiseaseandhepatocellular carcinoma:
The plot thickens
which these assessments can accurately reﬂect liver hepcidin
expression or iron content in complex clinical settings, compris-
ing multiple confounding factors, remains to be clariﬁed. Never-
theless and without any doubt, such studies are of obvious
medical and biological interest, although their interpretation will
likely be complicated.
In that respect, the regulation of hepcidin production is
complex and is affected, not only by iron metabolism, but also
by various hepatic factors; by inﬂammation, erythropoietic drive,
hypoxia etc. [4]. Moreover, hepcidin has a short half-life and
displays a circadian rhythm [8]. Even more challenging will be
to dissect whether the altered hepcidin levels represent a cause
or consequence of liver disease/ﬁbrosis progression. Finally, the
deleterious effects of iron metabolism in liver carcinogenesis
are further modulated by complex genetic factors at both the
constitutional and functional levels; indeed, multiple genetic
traits seem to impact hepatic iron content in patients with
chronic liver disease [9]. While in-depth transcriptomic analyses
reveal that expression of the HAMP gene could participate in a
reﬁnement of molecular classiﬁcation of HCCs [10].
In conclusion, although the road ahead will likely be bumpy, it
will be challenging to uncover the complex interaction between
liver disease and iron metabolism. These interactions are now
more important than ever given the rapid emergence of
hepcidin-targeted therapeutic strategies that could be further
modulated by host- and/or tumour-related genetic factors in
the setting of personalized medicine.
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JOURNAL OF HEPATOLOGYTo the Editor:
We read with interest the letter by Kessler et al. [1] that demon-
strated decreased hepcidin levels in various stress situations as
well as in hepatocellular carcinoma. Lowered hepcidin levels seen
in diethylnitrosamine-treated mice nicely complement earlier
data on mice subjected to thioacetamide-induced liver ﬁbrosis
or administered Lieber-DeCarli diet (an experimental model of
alcoholic liver disease), and suggest that diminished hepcidin
levels represent a common reaction to various liver stresses
[1–3]. Similarly, observations predominantly made in hepatitis
B-infected patients extend previous ﬁndings, obtained in subjects
with chronic liver disease due to hepatitis C infection or excessive
alcohol intake, which all display reduced liver hepcidin levels
[1,4]. Most importantly, in an elegant molecular analysis, Kessler
et al. also showed that hepatocellular carcinomas exhibit dimin-
ished hepcidin expression, that was previously reported only in
smaller studies.
Since hepcidin represents the central negative regulator of
iron metabolism [4], these data reinforce the hypothesis that
chronic liver disorders may promote development of acquired
iron overload again triggering the progression of liver ﬁbrosis
and/or development of hepatocellular carcinoma. As an underly-
ing mechanism, iron overload has multiple deleterious down-
stream effects, such as formation of reactive oxygen species,
mitochondrial or lysosomal injury [5,6]. However, while several
reports demonstrated an association between increased hepatic
iron load and progression of liver ﬁbrosis and/or HCC develop-
ment [7], no such studies are available for hepcidin. This is rather
surprising given the availability of multiple assays that can con-
veniently assess hepcidin serum levels. However, the extent toJournal of Hepatology 2015 vol. 62 j 975–989 979
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HCC and liver disease risks in homozygous PNPLA3 p.I148M
carriers approach monogenic inheritance
To the Editor:
The study published in the Journal of Hepatology by Liu et al. [1]
has robustly validated a strong genetic association between the
common PNPLA3 variant p.I148M and the risk of developing
hepatocellular carcinoma (HCC), in patients with non-alcoholic
fatty liver disease (NAFLD), also reported previously [2]. The asso-
ciation study [1] comprised 100 individuals with NAFLD-associ-
ated HCC and 1,476 controls and showed that homozygous
carriers of the p.148M mutation carry a 12-fold increased HCC
risk (odds ratio [OR] = 12.19, 95% conﬁdence interval = 6.89–
21.58, p <0.0001) as compared to p.I148 homozygotes. The mag-
nitude of this risk is remarkable and comparable to another
inherited liver disease, i.e., hereditary haemochromatosis. This
disease is due to HFE gene mutations and it represents a mono-
genic (‘Mendelian’) liver disorder [3].
Table 1A shows that the OR for HCC development is compara-
ble between HFE-associated haemochromatosis and PNPLA3-
associated fatty liver disease. A meta-analysis on haemochroma-
tosis, encompassing in total 320 HCC cases and almost 2,000 con-
trols from Europe and China [4], showed that homozygous
carriers of the HFE mutation p.282Y have a 12-fold increased risk
of developing liver disease (Table 1A). Interestingly, carriers of
HFE and PNPLA3 mutations may develop HCC even without cir-
rhosis [5,6].
Overall, both PNPLA3 p.I148M and HFE p.C282Y mutations
pose comparable risks for developing liver disease. Interestingly,
studies showed the PNPLA3 p.148M allele has been associated
with a 2- to 7-fold increased risk for fatty liver, steatohepatitis,
and ﬁbrosis [7,8]. This effect magnitude is comparable to the 4-
to 10-fold increased risk of liver disease and steatohepatitis,
respectively, in homozygous carriers of the HFE mutation [4]
(Table 1B). Similarly, the interaction between the genetic variant
and alcohol consumption promotes the development of clinically
relevant liver disease for both PNPLA3 and HFE mutations [9,10].
The frequency of the PNPLA3 p.I148M mutation in the general
population is higher than the frequency of the HFE p.C282Ymuta-
tion (Table 1B). This results in an a priori higher chance of carry-
ing the PNPLA3 rather than HFE variant in NAFLD-associated HCC.
However, whereas HFE-associated haemochromatosis repre-
sents a well-recognized monogenic disease, PNPLA3-associated
steatohepatitis currently does not. We conclude that given the
remarkably high risk of HCC secondary to NAFLD for PNPLA3
p.148M homozygotes, there is a need for additional systematic
studies with long-term follow-up. Finally, well-powered genetic
studies to investigate the risk of HCC conferred by combinations
of HFE and PNPLA3 mutations might be envisioned.
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